COMPUTEX-TAIPEI
For five incredible days, COMPUTEX TAIPEI 2014 showed its clout in shaping the future. COMPUTEX TAIPEI is the place where “ideas” are transformed into products ready for the market. It’s also the top choice for major international brands to announce new products, new technology, and new trends.
Buyers up 15% from China, 22% from UAE, 19% from Philippine!
COMPUTEX TAIPEI 2014 attracted 38,662 international buyers from 166 countries, an overall 1% growth. The top 10 nations by turnout were: China, USA, Japan, Hong Kong, Korea, Singapore, Thailand, Malaysia, Germany, and Russian Federation. There were notable increases in visitors from China (15% growth from last year), UAE (22% growth) and 19% growth for visitors from Philippine. It is projected that total visitor count for all five days will reach 130,000.
During the show, TAITRA organized 1,840 1-on-1 procurement meetings directly linking buyers with exhibitors. Key buyers included SIEMENS AG, Hisense, Toshiba, MA Laboratories, and Best Buy.
Ideas meet innovations at COMPUTEX TAIPEI
There were over 45 new product announcements held during the show and hundreds and thousands of “ideas” and innovations showcased.
ASUS beams up convergence
With a passion, ASUS has embraced convergence for the ultimate digital life. At COMPUTEX, it launched its Transformer Book V, the world’s first five-mode, three-in-one converged laptop that includes a Windows and Android laptop, tablet and smartphone. Other ASUS stars were the ASUS Fonepad and MeMO Pad Series.
FORD, Transactional Cars & You!
Ford rolled out the future in the form of its Vehicle-to-Vehicle (V2V) communication technology. Its smart V2V tech prevents accidents due to embedded ICT that let cars interact with other cars so drivers can sense through their cars pile-up and traffic jams. FORD also used this show to introduce to Taiwan its Emergency Assistance.
Acer clips on wearables & cloud
Acer launched its Liquid Leap wearable device with Liquid Jade smartphone. It’s "Build your own cloud" (BYOC) service is looking to turn PCs into personal data centers.
Meanwhile . . .
- Microsoft unveiled two new Windows devices
- Intel introduced its first 14-nanometer Broadwell processor especially for tablets.
- Broadcom released its latest processor focused on safety, multi-media and boosted communication capacity.
- MediaTek announced its platform “LinkIt” for wearable devices and internet of things.
- Corning presented the antimicrobial gorilla glass, which is world’s first anti-bacterial glass.
- E-ink showcased its latest 32-inch color e-paper screen.
- MiTAC announced its first wearable solution for health management.
Viewing ICT future thru CPX FORUMS
During the five-day show 120 speeches and forums were held that focused on every facet of ICT. While on stage at the SUMMIT Forum, Stan Shih, founder & president of Acer and M.K. Tsai, CEO of MediaTek, jointly announced their joint endeavors to explore prospects in cloud computing technology and IoT applications.
Nick Parker, Vice President of Microsoft Corporate, announced free Windows license fee for devices smaller than 9 inches at the MICROSOFT FORUM.
Renee James emphasized in her keynote speech at the e21FORUM, “Technology is a journey, not a destination.” The computer industry is not vanishing but integrating into smart phones, tablets, laptops and wearable devices.
COMPUTEX TAIPEI d&i awards beam up next era of ICT
The highly coveted award: the COMPUTEX d&i gold award was presented to 5 companies: GP Acoustics (UK) Ltd. for its X300A Wireless digital Hi-Fi speaker system; Philips for Philips Two-in-One Design, dual 19-inch display; HTC for the HTC Dot View case; Taer Innovation Co., Ltd. for Cylinder, cell phone car holder and Thermaltake Technology Co., Ltd. for Level 10 M Hybrid mouse.
Other winners include ASUSTek, Ace, Sandisk, ADATA, Qualcomm and many more.
A total of 75 winning products were chosen for the awards from 288 product entries. With the growing popularity of the Awards, more than 21,000 visitors enjoyed the COMPUTEX d&i awards pavilions at NANGANG Exhibition Hall during the show.
COMPUTEX TAIPEI 2015 to open next galaxy of innovation!
See a whole new galaxy of innovations only at COMPUTEX TAIPEI 2015 as it unfolds next year from June 2 to June 6.
For further details, check out: www.ComputexTaipei.com.tw
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140609005463/en/
Contact:
Exhibition Dept., TAITRA
Belinda Chen, +886-2-2725-5200 Ext 2636
press@taitra.org.tw
Fax:
+886-2-2725-3501
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum